Moderna to Reveal Breakthrough Skin Cancer Vaccine Data Ahead of Investor Meeting

2026-09-21 companies

Cambridge, Monday, 21 September 2026.
Moderna will present Phase 3 data for its personalized mRNA skin cancer vaccine at ESMO 2026, marking a historic first for mRNA cancer treatments after cutting recurrence risks.

ESMO Congress Presentation and Trial Specifics

Moderna (NASDAQ: MRNA) announced on September 21, 2026, that late-breaking Phase 3 data for intismeran autogene will be presented at the ESMO Congress 2026 in Madrid, Spain [1]. The data focuses on the adjuvant treatment of patients with resected stage IIB-IV melanoma and has been selected for a Presidential Symposium [1]. This investigational mRNA-based individualized neoantigen therapy is being jointly developed with Merck (NYSE: MRK), known as MSD outside the US and Canada [6]. The Phase 3 INTerpath-001 study evaluates the combination of intismeran autogene plus pembrolizumab versus pembrolizumab alone [1]. The trial enrolled 1,137 patients and met its primary endpoint of recurrence-free survival alongside the key secondary endpoint of distant metastasis-free survival [7].

Clinical Endpoints and Regulatory Status

The combination regimen represents the first to demonstrate statistically significant and clinically meaningful improvements over pembrolizumab monotherapy in this setting [6]. Investigators continue to monitor patients for secondary endpoints, including overall survival, as the study protocol dictates ongoing evaluation [6]. As of September 21, 2026, intismeran autogene remains investigational with no FDA approvals, though it previously received Breakthrough Therapy Designation [8]. The companies plan to engage with regulatory authorities regarding filing submissions following the data presentation [7]. [alert! ‘specific regulatory filing dates have not been confirmed in provided sources’]

Market Reaction and Investor Calendar

Market reaction to the clinical progress was evident prior to the formal announcement, with Moderna stock trading at USD 158.07 on September 17, 2026, an increase from the prior close of USD 145.62 [4]. This price movement reflects a percentage increase of 8.55 following positive Phase 3 melanoma vaccine data [4]. Analyst ratings remain mixed, with consensus price targets varying significantly across firms [4]. To discuss the clinical findings and strategic implications, Moderna will host a dedicated investor webcast on October 24, 2026 [1]. The event is scheduled for 7:00 PM CEST and will be archived on the company’s investor website for a minimum of 30 days [1].

Pipeline Expansion and Future Trials

Beyond melanoma, Moderna and Merck are evaluating intismeran in combination with pembrolizumab across multiple tumor types including lung, bladder, and kidney cancers [6]. Active Phase 3 recruiting trials for the therapy include INTerpath-002 and INTerpath-014 for non-small cell lung cancer (NSCLC) [8]. Two poster presentations regarding pancreatic ductal adenocarcinoma and Stage I NSCLC are also scheduled for the ESMO Congress [1]. This broader evaluation underscores the companies’ intent to leverage the mRNA platform beyond infectious disease vaccines [1]. The success in melanoma marks a historic first for mRNA cancer treatments after cutting recurrence risks [3].

Sources

Biotechnology Clinical Trials